INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream
Incyte secures FDA nod for Opzeluras pediatric use in atopic dermatitis, marking its third U.S. approval and boosting sales momentum.
INCY Announces New Late-Stage Data on Skin Disease Drug
Incyte's povorcitinib shows strong 24-week STOP-HS data in hidradenitis suppurativa, supporting 2025-2026 regulatory filings.
Incyte Corporation (INCY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)
Incyte Corporation (NASDAQ:INCY ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:45 AM EDT Company Participants William Meury - CEO, President & Director Pablo Cagnoni - President and Head of Research & Development Conference Call Participants Derek Archila - Wells Fargo Securities, LLC, Research Division Presentation Derek Archila Senior Equity Analyst All right, everyone. I think we'll get started here with our next fireside this morning.
Incyte Corporation (INCY) Presents At Cantor Global Healthcare Conference 2025 Transcript
Incyte Corporation (NASDAQ:INCY ) Cantor Global Healthcare Conference 2025 September 3, 2025 8:00 AM EDT Company Participants William Meury - CEO, President & Director Pablo Cagnoni - President and Head of Research & Development Conference Call Participants Eric Schmidt - Cantor Fitzgerald & Co., Research Division Emma Nealon Presentation Eric Schmidt Research Analyst Good morning, everyone. My name is Eric Schmidt.
Incyte: Wall Street Underestimates Strength Of Ruxolitinib Portfolio
Incyte's share price continues to soar despite Trump's repeated threats to cut drug prices. One of the key reasons behind the continued upward momentum was Incyte's strong financial results for Q2 2025. In particular, I was pleased with the sales of its emerging diamond called Niktimvo, which amounted to $36.2 million, an increase of 166.2% quarter-on-quarter.
INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?
Incyte hits a fresh 52-week high on strong Jakafi and Opzelura sales, pipeline wins and upbeat investor sentiment.
Why Incyte (INCY) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Incyte Corporation (INCY) Q2 2025 Earnings Call Transcript
Incyte Corporation (NASDAQ:INCY ) Q2 2025 Earnings Conference Call July 29, 2025 8:00 AM ET Company Participants Christiana Stamoulis - Executive VP & CFO Greg Shertzer - Senior Director of Investor Relations Mohamed Issa - Executive Vice President & Head of U.S. Oncology Pablo J. Cagnoni - President and Head of Research & Development William Meury - CEO, President & Director Conference Call Participants Brian Corey Abrahams - RBC Capital Markets, Research Division Conor Thomas MacKay - BMO Capital Markets Equity Research David Neil Lebowitz - Citigroup Inc., Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Jessica Macomber Fye - JPMorgan Chase & Co, Research Division Marc Alan Frahm - TD Cowen, Research Division Michael Werner Schmidt - Guggenheim Securities, LLC, Research Division Salim Qader Syed - Mizuho Securities USA LLC, Research Division Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Srikripa Devarakonda - Truist Securities, Inc., Research Division Stephen Douglas Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Tazeen Ahmad - BofA Securities, Research Division Yuxi Dong - Jefferies LLC, Research Division Operator Greetings, and welcome to the Incyte Second Quarter 2025 Earnings Conference Call and Webcast.
Incyte (INCY) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Incyte (INCY) Surpasses Q2 Earnings and Revenue Estimates
Incyte (INCY) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.39 per share. This compares to a loss of $1.82 per share a year ago.
Incyte lifts annual sales forecast for blood cancer drug after solid quarter
Incyte Corp on Tuesday raised its annual sales forecast for blood cancer treatment Jakafi after robust demand helped the company surpass Wall Street estimates for second-quarter revenue and profit.
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
INCY eyes strong Q2 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
